Ottimo Pharma

About Ottimo Pharma

Ottimo Pharma is a biotech company focused on developing first-in-class, bi-functional medicines, specifically PD1/VEGFR2 dual pathway antibodies, to extend the lives of people living with cancer.

Products & Services

PD1/VEGFR2 Dual Pathway Antibodies:First-in-class, one-of-a-kind antibodies designed to target dual pathways for cancer treatment, aiming to extend patient lives.

Specialties

Oncology Bi-functional Medicines PD1/VEGFR2 Dual Pathway Antibodies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 140000000 MR: - FA: over $140 million FAN: 140000000	D: 2024-12-19 FD: 2024-12-19	9 investors

Series A Latest

2024-12-19

$140.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Epstein

Chair & Chief Executive Officer

M

Mehdi Shahidi

Head of Development & Chief Medical Officer

L

Ling Zeng

General Counsel and EVP of Execution

S

Spencer Fisk

Chief Technical and Quality Officer

J

Jonny Finlay

Founder and Chief Scientific Advisor

R

Rick Anderson

SVP Finance

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Ottimo Pharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised